TFF Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- TFF Pharmaceuticals's estimated annual revenue is currently $3.2M per year.
- TFF Pharmaceuticals's estimated revenue per employee is $84,632
- TFF Pharmaceuticals's total funding is $48.2M.
Employee Data
- TFF Pharmaceuticals has 38 Employees.
- TFF Pharmaceuticals grew their employee count by 41% last year.
TFF Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $62.5M | 0 | N/A | N/A | N/A |
#4 | $8.8M | 41 | 5% | N/A | N/A |
#5 | $58.3M | 491 | 28% | N/A | N/A |
#6 | $21.3M | 94 | 7% | N/A | N/A |
#7 | $78.6M | 382 | 8% | N/A | N/A |
#8 | $12.3M | 46 | -8% | N/A | N/A |
#9 | $6M | 29 | 7% | N/A | N/A |
#10 | $53.6M | 417 | 44% | $1.4B | N/A |
What Is TFF Pharmaceuticals?
TFF Pharmaceuticals, Inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology. Our patented Thin Film Freezing (TFF) platform makes it possible to turn more molecules into inhalable therapies. This novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally.
keywords:N/A
$48.2M
Total Funding
38
Number of Employees
$3.2M
Revenue (est)
41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TFF Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Manager, Process Engineering | Reveal Email/Phone |
2 | VP, Product Development and Manufacturing | Reveal Email/Phone |
3 | Vice Chairman, President & CEO | Reveal Email/Phone |
4 | CFO | Reveal Email/Phone |
5 | Director, Global Strategic Marketing and Analytics | Reveal Email/Phone |
6 | Chief Operating Officer and VP, Business Development | Reveal Email/Phone |
7 | VP Government and Strategic Initiatives | Reveal Email/Phone |
8 | Clinical Development Lead/Medical Monitor | Reveal Email/Phone |
9 | CEO | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
TFF Pharmaceuticals News
TFF Pharmaceuticals believes the 6 mg dose level of Niclosamide Inhalation Powder is estimated to produce a concentration of 100 ?M in the...
TFF Pharmaceuticals, Inc. ( TFFP -2.85% ) Q4 2021 Earnings Call Mar 24, 2022, 4:30 p.m. ET. Contents: Prepared Remarks; Questions and...
Benzinga Pro data, TFF Pharmaceuticals. TFFP-6.33%+ Free Alerts. reported Q4 sales of $12.00 thousand. Earnings fell to a loss of $10.05...
Initial data from Phase 1b showed Voriconazole Inhalation Powder is Well Tolerated in Asthma Patients Data Supports Progress to Phase 2 and Inclusion of Patients with Asthma AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceu ...
AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced topline re ...
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $4.8M | 38 | -3% | N/A |
#2 | $4M | 38 | 6% | $2.5M |
#3 | $4.9M | 38 | -5% | N/A |
#4 | $6.6M | 38 | 9% | N/A |
#5 | $4.7M | 38 | -7% | $273.4M |